Indonesia Moves to Curb Drug Patent 'Evergreening': What to Know
Indonesia's Constitutional Court has revived limits on drug patent claims. Here's what the ruling means for generic medicines and access to treatment.
Indonesia's Constitutional Court has reinstated a provision that aims to curb drug patent evergreening, a practice that extends patent protection without significant innovation. This decision could help prevent pharmaceutical companies from monopolizing existing medicines and keep generic alternatives accessible. The ruling has been welcomed by patient advocacy groups who argue that it would make medicines more affordable and accessible to patients.
Written by urgent.news from Tempo.co English's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
